You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Colorcon
Medtronic
Dow
Johnson and Johnson

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CB-839


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug CB-839?

CB-839 is an investigational drug.

There have been 20 clinical trials for CB-839. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2017.

The most common disease conditions in clinical trials are Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are Calithera Biosciences, Inc, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.

There are nine US patents protecting this investigational drug and one hundred and seven international patents.

Recent Clinical Trials for CB-839
TitleSponsorPhase
A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCCalithera Biosciences, IncPhase 2
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 1
CB-839 in Combination With Niraparib in Platinum Resistant Breast Cancer (BRCA) -Wild-type Ovarian Cancer PatientsUniversity of Alabama at BirminghamPhase 1

See all CB-839 clinical trials

Clinical Trial Summary for CB-839

Top disease conditions for CB-839
Top clinical trial sponsors for CB-839

See all CB-839 clinical trials

US Patents for CB-839

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CB-839   Start Trial Combination therapy with glutaminase inhibitors Calithera Biosciences, Inc. (South San Francisco, CA)   Start Trial
CB-839   Start Trial Compositions and methods of treating cancer harboring PIKC3A mutations Case Western Reserve University (Cleveland, OH)   Start Trial
CB-839   Start Trial Combination therapy with glutaminase inhibitors and immuno-oncology agents Calithera Biosciences, Inc. (South San Francisco, CA)   Start Trial
CB-839   Start Trial Combination therapy with glutaminase inhibitors Calithera Biosciences, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CB-839

Drugname Country Document Number Estimated Expiration Related US Patent
CB-839 China 109982703 2036-08-25   Start Trial
CB-839 European Patent Office 3503893 2036-08-25   Start Trial
CB-839 Japan 2019524852 2036-08-25   Start Trial
CB-839 World Intellectual Property Organization (WIPO) 2018039441 2036-08-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKinsey
Express Scripts
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.